Provivi is an emerging crop-protection company developing scalable pheromone solutions for pest and resistance management in large-acreage crops such as corn, rice, and soy. Its patented production method lowers the cost of manufacturing pheromones, enabling use in high-acreage row crops. Provivi has registered and commercialized its technology in Mexico, Brazil, and Kenya. The company focuses on pheromone-based Mating Disruption to selectively control pests while preserving beneficial insects and reducing harmful residues. Provivi plans projects to develop and supply products against Rice Stem Borer and Maize Fall Armyworm to small-scale farmers in Kenya, Bangladesh, and India. Financially, the company announced a $10M investment from the Bill & Melinda Gates Foundation that adds to a recently announced $45.5M Series C-2 fundraising round. Provivi develops a family of pheromone-based solutions for crop protection, targeting crops such as corn, rice and soy. Its products use insect pheromones to control damaging pests while preserving beneficial insects. The company intends to commercialize and launch its pheromone product line. Provivi was founded in 2013 by Dr. Pedro Coelho, Dr. Peter Meinhold and 2018 Nobel laureate Dr. Frances Arnold. The firm is based in Santa Monica, California. It completed a significant Series C financing to support its commercialization plans. Provivi develops bio-based pest control technologies using biological and innovative chemical processes. The company leverages scientific discoveries at the California Institute of Technology and its own technological developments. It produces supply-limited products for agriculture, commercial, household, and public health pest management. Within crop agriculture Provivi leverages molecules used by insects for communication to develop pest control solutions. Its agricultural solutions are intended to fit into Organic, Conventional and GMO practices. The company intends to use the funds from the Series A to advance its solutions.

Total raised

$95M

Funding rounds

3

Latest round

Equity

Latest activity

Jul 2024